228 related articles for article (PubMed ID: 37285013)
1. Glofitamab: First Approval.
Shirley M
Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
Polgarova K; Trneny M
Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
[TBL] [Abstract][Full Text] [Related]
3. Epcoritamab: First Approval.
Frampton JE
Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
[TBL] [Abstract][Full Text] [Related]
4. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
[TBL] [Abstract][Full Text] [Related]
5. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
[TBL] [Abstract][Full Text] [Related]
6. [New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].
Chiche E; Loschi M
Bull Cancer; 2022 Sep; 109(9):879-880. PubMed ID: 35717220
[No Abstract] [Full Text] [Related]
7. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
9. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
10. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
14. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M
Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996
[TBL] [Abstract][Full Text] [Related]
16. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
Cassanello G; Luna de Abia A; Falchi L
Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
[TBL] [Abstract][Full Text] [Related]
17. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
[TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]